Autoimmunity in scleroderma: The origin, pathogenetic role, and clinical significance of autoantibodies

Michelle L. Harris, Antony Rosen

Research output: Contribution to journalReview articlepeer-review

75 Scopus citations


Purpose of review: Systemic sclerosis, or scleroderma, is a systemic autoimmune disease manifest by vascular damage and fibrosis within the skin and visceral organs. Whereas scleroderma is a heterogenous disorder in terms of disease symptoms and clinical course, scleroderma-specific autoantibody profiles associate strongly with distinct clinical phenotypes, making serologic testing of great diagnostic aid. This review will focus on the clinical significance and the potential pathogenic role of autoantibodies in scleroderma. Recent findings: Novel autoantibody and phenotype associations discovered within the past year underscore the clinical utility of systemic sclerosis-associated autoantibodies. Whereas autoantibodies are generally believed to indicate the presence of ongoing tissue damage, some research suggests that the humoral immune response may play a role in generating such damage. Summary: Improvements in multiplex autoantibody assays will aid in the diagnosis and prognosis of the complications associated with systemic sclerosis. Continued research into autoantibody/phenotype associations could also yield critical insights into the pathogenesis of, and suggest novel therapeutic targets for, this chronic, debilitating disease.

Original languageEnglish (US)
Pages (from-to)778-784
Number of pages7
JournalCurrent opinion in rheumatology
Issue number6
StatePublished - Nov 2003


  • Autoantibody
  • Pathogenesis
  • Scleroderma
  • Systemic sclerosis

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Autoimmunity in scleroderma: The origin, pathogenetic role, and clinical significance of autoantibodies'. Together they form a unique fingerprint.

Cite this